Changes of TLR2, TLR4 and MyD88 mRNA expressions on peripheral blood mononuclear cell in severe sepsis patients during treatment with Thymosin α1

doi:10.3877/cma.j.issn.1674-0793.2014.04.004

Abstract

Abstract:

Objective

To examine the TLR2, TLR4 and MyD88 mRNA expressions on human peripheral blood mononuclear cells during treatment.

Methods

A prospective randomized controlled trial was designed. Fifty-four patients with severe sepsis were enrolled and randomized into thymosin group (26 cases, treated with thymosin alpha 1) and control group (28 cases). TLR2, TLR4 and MyD88 mRNA were tested by RT-PCR on the day of enrollment, day 3 and day 7 after treatment in both groups, 28-day mortality in these patients was analyzed.

Results

There was no statistically significant difference between 28-day mortality rate in the control group and that of thymosin group (35.7% vs 23.1%, P=0.310). TLR2, TLR4 and MyD88 mRNA expressions in the thymosin group were respectively increased on enrollment day, day 3 and day 7, while this increasing trend was not found in the control group. On day 3, TLR2 and TLR4 mRNA expressions in the thymosin group were higher than those in the control group (2.31±0.79 vs 1.83±0.51, 7.31±0.79 vs 6.55±0.92, P<0.05). On day 7, TLR2, TLR4 and MyD88 mRNA expressions in the thymosin group were higher than those in the control group (2.75±1.17 vs 1.63±0.36, 7.75±1.03 vs 6.39±0.72, 4.26±0.77 vs 3.77±0.68, P<0.05).

Conclusion

Thymosin alpha 1 may increase TLR2, TLR4 and MyD88 mRNA expressions in severe sepsis patients.

Key words: Sepsis, Thymosin alpha 1, Toll like receptor, Myeloid differentiation factor 88

Jianfeng Wu, Zhaoxia Tang, Juan Chen, Bin Ouyang, Minying Chen, Xiangdong Guan. Changes of TLR2, TLR4 and MyD88 mRNA expressions on peripheral blood mononuclear cell in severe sepsis patients during treatment with Thymosin α1[J]. Chinese Archives of General Surgery(Electronic Edition), 2014, 08(04): 270-274.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2014.04.004

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2014/V08/I04/270

Figures/Tables 7

References 13

[1]	李铁男,周立新,强新华, 等. 连续血液净化和胸腺肽α1对严重脓毒症细胞免疫及预后的前瞻性随机对照研究[J]. 中国危重病急救医学, 2009, 21(3): 139-142.
[2]	黄顺伟,管向东,陈娟, 等. 创伤性严重脓毒症和多器官功能障碍综合征免疫调理治疗的临床研究和远期评价[J]. 中国危重病急救医学, 2006, 18(11): 653-656.
[3]	Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine[C]. Chest, 1992, 101(6): 1644-1655.
[4]	Hotchkiss RS,Karl IE. The pathophysiology and treatment of sepsis[J]. N Engl J Med, 2003, 348(2):138-150.
[5]	黄顺伟,管向东,陈娟, 等. 免疫调理对脓毒症大鼠中性粒细胞和淋巴细胞亚群的影响[J/CD]. 中华普通外科学文献:电子版, 2009, 3(5):1-1.
[6]	Akira S,Takeda K,Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity[J]. Nat Immunol, 2001, 2(8): 675-680.
[7]	王瑞晨,胡森. 脓毒症、严重脓毒症和脓毒性休克患者的中性粒细胞与外周血单核细胞具有不同的Toll样受体信号调节通路[J]. 中国危重病急救医学, 2009, 21(1): 50.
[8]	Rigato O,Salomao R. Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis[J]. Shock, 2003, 19(2): 113-116.
[9]	Garaci E. Thymosin alpha1: a historical overview[J]. Ann N Y Acad Sci, 2007, 1112: 14-20.
[10]	Romani L,Bistoni F,Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling[J]. Blood, 2004, 103(11): 4232-4239.
[11]	Peck-Palmer OM,Unsinger J,Chang KC, et al. Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis but worsens survival[J]. J Leukoc Biol, 2008, 83(4): 1009-1018.
[12]	De Luca A,Montagnoli C,Zelante T, et al. Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc[J]. J Immunol, 2007, 179(9): 5999-6008.
[13]	Takeuchi O,Takeda K,Hoshino K, et al. Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades[J]. Int Immunol, 2000, 12(1): 113-117.

引物名称	上游引物	下游引物	探针
TLR2	CACTGCTTTCAACTGGTAGTTG	TCCACAGGCTGATGATGATGACC	GACCCACACCATCCACAAAGTATGTGGC
TLR4	CTGCAGGTGCTGGATTTATC	CAATATTAAGGTAGAGAGGTGGC	GCTCTGATATGCCCCATCTTCAATTGTCTG
MyD88	GACCAAATTTGCACTCAGCC	GGGAACTCTTTCTTCATTGCC	GTACTTGATGGGGATCAGTCGCTTCTGATG
β-actin	GGATGCAGAAGGAGATCACTG	CGATCCACACGGACTACTTG	CAGGAGGAGCAATGATCTTGATCTTCATTGTGC

引物名称	上游引物	下游引物	探针
TLR2	CACTGCTTTCAACTGGTAGTTG	TCCACAGGCTGATGATGATGACC	GACCCACACCATCCACAAAGTATGTGGC
TLR4	CTGCAGGTGCTGGATTTATC	CAATATTAAGGTAGAGAGGTGGC	GCTCTGATATGCCCCATCTTCAATTGTCTG
MyD88	GACCAAATTTGCACTCAGCC	GGGAACTCTTTCTTCATTGCC	GTACTTGATGGGGATCAGTCGCTTCTGATG
β-actin	GGATGCAGAAGGAGATCACTG	CGATCCACACGGACTACTTG	CAGGAGGAGCAATGATCTTGATCTTCATTGTGC

组别	例数	年龄（岁，±s）	性别（男/女）	APACHE Ⅱ评分（±s）	SOFA评分（±s）	28 d病死率[%(n)]
对照组	28	61.2±11.0	20/8	19.5±5.4	7.2±3.2	35.7（10）
治疗组	26	60.2±12.3	21/5	20.1±7.1	7.6±3.1	23.1（6）
t/χ²值	?	1.190^a	0.379^b	0.812^a	0.533^a	0.530^b
P值	?	0.582	0.237	0.622	0.661	0.316

组别	例数	年龄（岁，±s）	性别（男/女）	APACHE Ⅱ评分（±s）	SOFA评分（±s）	28 d病死率[%(n)]
对照组	28	61.2±11.0	20/8	19.5±5.4	7.2±3.2	35.7（10）
治疗组	26	60.2±12.3	21/5	20.1±7.1	7.6±3.1	23.1（6）
t/χ²值	?	1.190^a	0.379^b	0.812^a	0.533^a	0.530^b
P值	?	0.582	0.237	0.622	0.661	0.316

组别		例数	TLR2(A)	TLR4(A)	MyD88(A)
对照组		28	?	?	?
?	治疗前	?	1.56±0.29	6.29±0.68	3.52±0.41
?	治疗后3天	?	1.83±0.51^a	6.55±0.92	3.63±0.72
?	治疗后7天	?	1.63±0.36	6.39±0.72	3.77±0.68
治疗组		26	?	?	?
?	治疗前	?	1.71±0.26	6.51±0.66	3.31±0.34
?	治疗后3天	?	2.31±0.79^b	7.31±0.79^b	3.71±0.67
?	治疗后7天	?	2.75±1.17^ab	7.75±1.03^ab	4.26±0.77^ab

Please choose a citation manager

Content to export